GRI Bio, Inc. (GRI)
$1.84+$0.03 (+1.66%) Latest session
Leanne Kelly - OfficerGRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
No Form 4 activity for GRI in the last 90 days.
18 Form 4 filings on record, the earliest from Aug 13, 2025, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Walter Marc Hertz - Officer | Grant or award | Stock Option (Right to Buy) | 103,067 | $0.00 | - | |
| Leanne Kelly - Officer | Grant or award | Stock Option (Right to Buy) | 43,222 | $0.00 | - | |
| David Leslie Szekeres - Director | Grant or award | Stock Option (Right to Buy) | 39,897 | $0.00 | - | |
| Roelof Rongen - Director | Grant or award | Stock Option (Right to Buy) | 23,605 | $0.00 | - | |
| Camilla V. Simpson - Director | Grant or award | Stock Option (Right to Buy) | 23,605 | $0.00 | - | |
| David Charles Baker - Director | Grant or award | Stock Option (Right to Buy) | 23,605 | $0.00 | - | |
| Vipin Chaturvedi - Officer | Grant or award | Stock Option (Right to Buy) | 43,222 | $0.00 | - | |
| Leanne Kelly - Officer | Grant or award | Stock Option (Right to Buy) | 11,854 | $0.00 | - | |
| Camilla V. Simpson - Director | Grant or award | Stock Option (Right to Buy) | 5,994 | $0.00 | - | |
| Walter Marc Hertz - Officer | Grant or award | Stock Option (Right to Buy) | 26,688 | $0.00 | - | |
| David Charles Baker - Director | Grant or award | Stock Option (Right to Buy) | 5,994 | $0.00 | - | |
| David Leslie Szekeres - Director | Grant or award | Stock Option (Right to Buy) | 10,276 | $0.00 | - | |
| Roelof Rongen - Director | Grant or award | Stock Option (Right to Buy) | 5,994 | $0.00 | - | |
| Vipin Chaturvedi - Officer | Grant or award | Stock Option (Right to Buy) | 11,854 | $0.00 | - | |
| David Charles Baker - Director | Grant or award | Stock Option (Right to Buy) | 4,527 | $0.00 | - | |
| David Leslie Szekeres - Director | Grant or award | Stock Option (Right to Buy) | 7,545 | $0.00 | - | |
| Camilla V. Simpson - Director | Grant or award | Stock Option (Right to Buy) | 4,527 | $0.00 | - | |
| Roelof Rongen - Director | Grant or award | Stock Option (Right to Buy) | 4,527 | $0.00 | - |
GRI Bio, Inc. (GRI) has filed no insider reports in the last 90 days. The most recent on record is dated 2025-09-18. The full record for GRI runs to 18 Form 4 filings, the earliest from 2025-08-13. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of GRI were filed in the last 90 days.
No insider sales of GRI were filed in the last 90 days.
This page tracks GRI Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add GRI to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
